Igurishwa ritaziguye riva mu Bushinwa CAS 1006376-62-0 (1R, 2R) -2- (3,4-difluorophenyl) cyclopropane carboxaMide Igurishwa Rishyushye

Ticagrelor ni imiti igabanya ubukana bwo mu kanwa, izina ryayo ryo muri Amerika ni Brilinta, naho izina ry’iburayi ni Brilique. Ticagrelor ni antasitori idasubirwaho ya platine adenosine diphosphate (ADP) reseptor antagonist yagenewe kubuza platine gufatana hamwe no gukora uturemangingo twamaraso dushobora gutera indwara zumutima ndetse nubwonko. Muri Amerika, ticagrelor yemejwe bwa mbere na FDA muri Nyakanga 2011 kugira ngo ivure abarwayi bakuze bafite syndrome ikaze ya coronary (ACS). Amavuriro yerekana ko ticagrelor ikora neza cyane kuruta clopidogrel mukugabanya urupfu rwumutima nimiyoboro byibura amezi 12 nyuma yibikorwa bya ACS. Byongeye kandi, ticagrelorChemicalbook yanagabanije kwandura stent trombose (ST) ku barwayi bari bahawe stent yo kuvura ACS. Muri Kamena 2020, AstraZeneca yatangaje ko Ikigo cy’Amerika gishinzwe ibiryo n’ibiyobyabwenge (FDA) cyemeje imiti igabanya ubukana bwa Brilinta (ticagrelor) kugira ngo ikoreshwe mu barwayi bafite indwara ziterwa n’imitsi y’imitsi (CAD) kugira ngo bagabanye ibyago byo kwibasirwa n’umutima wa mbere. cyangwa ibyago byo guhagarara k'ubwonko. Mu Gushyingo 2020, AstraZeneca yatangaje ko Ikigo cy’Amerika gishinzwe ibiryo n’ibiyobyabwenge (FDA) cyemeje ikimenyetso gishya kuri anticagulant Brilinta (ticagrelor), ifatanije na aspirine, kugira ngo bavure ischemie ikaze. Ku barwayi bafite ikibazo cyo kuva amaraso cyangwa kuvura indwara ziterwa na ischemic transitime (TIA), bigabanya ibyago byo guhura nubwonko.